Abstract
Combination of BRAF inhibitors and anti-EGFR antibodies is a standard of 2nd and subsequent line of treatment in pts with mBRAF mCRC. We performed analysis of prospective multicentric database of pts with mBRAF metastatic CRC to evaluate the efficacy of such approach in the real clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
